In bladder cancer clinical trials in Europe, the recombinant BCG vaccine has demonstrated potent ... Total time from vial puncture to the completion of the intravesical instillation should not ...
BCG is one of the most widely used vaccines worldwide ... Instill intravesically only after dilution. Total time from vial puncture to the completion of the intravesical instillation should ...
BCG is one of the most widely used vaccines worldwide ... Instill intravesically only after dilution. Total time from vial puncture to the completion of the intravesical instillation should ...
Fresenius Kabi, an operating company of Fresenius, and Formycon AG, a leading, independent developer of high-quality ...
Otulfi in a 45 mg/0.5 mL single-dose vial for subcutaneous injection ... should not receive live vaccines. Avoid administering BCG vaccines during treatment with OTULFI (ustekinumab-aauz), or ...
The four approved presentations of SELARSDI are 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled syringe for subcutaneous ...
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional ...
The four approved presentations of SELARSDI are 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled syringe for subcutaneous injection, 45 mg/0.5 mL in a single-dose vial for subcutaneous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback